Merck Canada says new drug price regulations are unconstitutional
By Allison Martell (Reuters) - Merck Canada and a group of pharmaceutical companies are challenging the constitutionality of new regulations meant to lower patented drug prices, the company said in a statement on Friday, in a late bid to derail reforms that would hurt pharmaceutical companies' earnings. The Canadian government announced final regulations that give new powers to the Patented Medicine Prices Review Board (PMPRB) earlier this month, and published them in an official register on Wednesday.
By Allison Martell
(Reuters) - Merck Canada and a group of pharmaceutical companies are challenging the constitutionality of new regulations meant to lower patented drug prices, the company said in a statement on Friday, in a late bid to derail reforms that would hurt pharmaceutical companies' earnings.
The Canadian government announced final regulations that give new powers to the Patented Medicine Prices Review Board (PMPRB) earlier this month, and published them in an official register on Wednesday. They go into force on July 1, 2020.
"Our position is that the federal government does not have the constitutional authority to regulate the prices of medicines and manage healthcare systems, which has always been provincial jurisdiction," Merck Canada said, adding the new rules "will slow and limit Canadians' access to new breakthrough medicines."
Health Canada, Canada's federal health department, did not immediately respond to a request for comment.
The filing ratchets up a confrontation between Prime Minister Justin Trudeau's Liberal government and the pharmaceutical industry ahead of an Oct. 21 national election.
The new regulations expand the information the PMPRB can consider when setting drug price caps, among other things, giving it the ability to consider cost-effectiveness, measured in quality-adjusted life years, for the first time.
The rules will save patients, employers, insurers and government drug plans money, at the expense of drug company profits in Canada. They could eventually have consequences in the United States, the world's largest pharmaceutical market.
The Trump administration said in July it would let U.S. states and others start pilot programs importing drugs from Canada. It has also said it may base what the U.S. government healthcare program Medicare pays for certain medicines based on prices in other countries, including Canada.
Drugmakers, represented in Canada by lobby group Innovative Medicines Canada, have argued that lower prices would delay drug launches, reduce investment in life sciences and drive new drug trials out of the country.
The federal government says other countries with lower drug prices have investment and drug access that is as good as or better than Canada's.
Staff at the PMPRB wrote in a briefing last year that Canada had accepted high prices since the 1980s in the hopes of attracting more research and development funding, but "the anticipated benefits haven't materialized and the regulatory pricing model is broken."
(Reporting by Allison Martell in Toronto; additional reporting by Kelsey Johnson in Ottawa; editing by Chris Reese and Jonathan Oatis)
This story has not been edited by Firstpost staff and is generated by auto-feed.
By Robin Emmott and John Irish | BRUSSELS/PARIS BRUSSELS/PARIS France and Germany will agree to a U.S. plan for NATO to take a bigger role in the fight against Islamic militants at a meeting with President Donald Trump on Thursday, but insist the move is purely symbolic, four senior European diplomats said.The decision to allow the North Atlantic Treaty Organization to join the coalition against Islamic State in Syria and Iraq follows weeks of pressure on the two allies, who are wary of NATO confronting Russia in Syria and of alienating Arab countries who see NATO as pushing a pro-Western agenda."NATO as an institution will join the coalition," said one senior diplomat involved in the discussions. "The question is whether this just a symbolic gesture to the United States
BEIJING Chinese President Xi Jinping on Wednesday called for greater efforts to make the country's navy a world class one, strong in operations on, below and above the surface, as it steps up its ability to project power far from its shores.China's navy has taken an increasingly prominent role in recent months, with a rising star admiral taking command, its first aircraft carrier sailing around self-ruled Taiwan and a new aircraft carrier launched last month.With President Donald Trump promising a US shipbuilding spree and unnerving Beijing with his unpredictable approach on hot button issues including Taiwan and the South and East China Seas, China is pushing to narrow the gap with the U.S. Navy.Inspecting navy headquarters, Xi said the navy should "aim for the top ranks in the world", the Defence Ministry said in a statement about his visit."Building a strong and modern navy is an important mark of a top ranking global military," the ministry paraphrased Xi as saying.